BioElectronics Expands ActiPatch to Taiwan Through Aphrodite Medical Group Partnership
BioElectronics Corporation's expansion of its FDA-cleared ActiPatch device to Taiwan through distributor Aphrodite Medical Group represents a significant shift toward drug-free pain management alternatives in Asian healthcare markets.
BioElectronics Corporation announced the commercial launch of its ActiPatch device in Taiwan through distributor Aphrodite Medical Group, marking a strategic expansion of drug-free pain management technology into Asian markets. The US FDA-cleared medical device delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level, providing up to 720 hours of continuous therapy as an alternative to pharmaceutical interventions.
The partnership with Aphrodite Medical Group establishes a clinical foundation for ActiPatch in Taiwan, leveraging the distributor's extensive healthcare network and clinical infrastructure. According to BioElectronics CEO Kelly Whelan, this collaboration positions the company to scale its therapy meaningfully in the Taiwanese market. The initial shipment of devices has been completed, with a coordinated market launch planned for the second quarter of 2026 focusing initially on musculoskeletal pain management.
This expansion reflects growing global demand for non-pharmaceutical pain management solutions as healthcare systems seek alternatives to opioid-based treatments. ActiPatch's drug-free approach addresses concerns about medication side effects and dependency while offering patients extended wear capability, including during sleep. The technology's FDA clearance provides regulatory validation that supports its introduction into international markets through established distribution channels.
Yang Pei-Hsien, Vice President of Aphrodite Medical Group, emphasized the alignment between ActiPatch technology and Taiwan's healthcare priorities, particularly the increasing demand for safe and effective pain management options. The rollout strategy includes physician engagement and patient access initiatives across Aphrodite Medical Group's clinical network, with potential for expansion into additional therapeutic applications over time.
BioElectronics' Taiwan entry represents a calculated market expansion through quality distribution partnerships, reinforcing the company's focus on clinically validated bioelectronic therapies. The move comes as healthcare providers worldwide increasingly integrate non-invasive technologies into pain management protocols, creating opportunities for devices that offer practical alternatives to traditional pharmaceutical approaches. More information about the company is available at https://www.bielcorp.com.